title: [Epigenetic cancer drugs and their role in anticancer therapy].
abstract: Epigenetic modification have been causally linked to cancer development and progression, and are potentially reversible by treatments with epigenetic cancer drugs. The aim of this review is to give an overview of the basic current knowledge on molecular mechanisms of epigenetic cancer drugs and their possible clinical use. Many of them are in in clinical trials. However only two demethylating agents ie. inhibitors of DNA methyltransferase (5- azacytidin and decitabin) are approved in the treatment of myelodysplastic syndrome and a few inhibitors of histonacetylase (vorinostat, romidepsin and panobinostat) are approved in the treatment of hematological malignancies, particularly in refractory or relapsed cutaneous T cell lymhoma.
authors.affiliation: Interní klinika 1. lékařské fakulty UK a VFN v Praze. pavel.klener@ruk.cuni.cz
authors.forename: P
authors.initials: P
authors.lastname: Klener
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use*; D044127:Epigenesis, Genetic / Q000187:drug effects*; D006801:Humans; D009369:Neoplasms / Q000188:drug therapy* / Q000235:genetics*
chemical_list: D000970:Antineoplastic Agents